BOUCHAL, Pavel, Monika DVOŘÁKOVÁ, Theodoros ROUMELIOTIS, Zbyněk BORTLÍČEK, Ivana IHNATOVÁ, Iva PROCHÁZKOVÁ, JTC HO, Josef MARYÁŠ, Hana IMRICHOVÁ, Eva BUDINSKÁ, Rostislav VYZULA, Spiros D, GARBIS, Bořivoj VOJTĚŠEK a Rudolf NENUTIL. Combined proteomics and transcriptomics identifies carboxypeptidase B1 and NF-kappa B associated proteins as putative biomarkers of metastasis in low grade breast cancer. In European Cancer Congress 2015, Vienna, Austria, 25.-29.9.2015 - European Journal of Cancer, Vol. 51, S3. Oxford: Elsevier Science Inc., 2015. s. S24-S25, 2 s. 2015. ISSN 0959-8049.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Combined proteomics and transcriptomics identifies carboxypeptidase B1 and NF-kappa B associated proteins as putative biomarkers of metastasis in low grade breast cancer
Autoři BOUCHAL, Pavel, Monika DVOŘÁKOVÁ, Theodoros ROUMELIOTIS, Zbyněk BORTLÍČEK, Ivana IHNATOVÁ, Iva PROCHÁZKOVÁ, JTC HO, Josef MARYÁŠ, Hana IMRICHOVÁ, Eva BUDINSKÁ, Rostislav VYZULA, Spiros D, GARBIS, Bořivoj VOJTĚŠEK a Rudolf NENUTIL.
Vydání European Cancer Congress 2015, Vienna, Austria, 25.-29.9.2015 - European Journal of Cancer, Vol. 51, S3. Oxford: Elsevier Science Inc., 2015. s. S24-S25, 2 s. 2015.
Další údaje
Originální jazyk angličtina
Typ výsledku Konferenční abstrakt
Obor 10600 1.6 Biological sciences
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 6.163
Organizační jednotka Přírodovědecká fakulta
ISSN 0959-8049
Klíčová slova anglicky proteomics; breast cancer
Příznaky Mezinárodní význam
Změnil Změnil: doc. Mgr. Pavel Bouchal, Ph.D., učo 8757. Změněno: 9. 1. 2019 21:20.
Anotace
Background: Current prognostic factors are insufficient for precise risk-discrimination in breast cancer patients with low grade breast tumors, which, in disagreement with theoretical prognosis, occasionally form early lymph node metastasis. Material and Methods: To identify markers for this group of patients, we employed iTRAQ-2DLC-MS/MS proteomics to 24 lymph node positive and 24 lymph node negative grade 1 luminal A primary breast tumors. Another group of 48 high-grade tumors (luminal B, triple negative, Her-2 subtypes) was also analyzed to investigate marker specificity for grade 1 luminal A tumors. Results: From the total of 4405 proteins identified (FDR<5%), the top 65 differentially expressed together with 30 previously identified and control markers were analyzed also at transcript level. Increased levels of carboxypeptidase B1 (CPB1), PDZ and LIM domain protein 2 (PDLIM2) and ring finger protein 25 (RNF25) were associated specifically with lymph node positive grade 1 tumors, whereas stathmin 1 (STMN1) and thymosin beta 10 (TMSB10) associated with aggressive tumor phenotype also in high grade tumors at both protein and transcript level. For CPB1, these differences were also observed by immunohistochemical analysis on tissue microarrays. Upregulation of putative biomarkers in lymph node positive (vs. negative) luminal A tumors was validated by gene expression analysis of an independent published dataset (N=343) for CPB1 (p=0.00155), PDLIM2 (p=0.02027) and RELA (p=0.00015). Moreover, statistically significant connections with patient survival were identified in another public dataset (N=1678). Conclusions: Our findings indicate unique pro-metastatic mechanisms in grade 1 tumors that can include up-regulation of CPB1, activation of NF-kappaB pathway and changes in cell survival and cytoskeleton. These putative biomarkers have potential to identify the specific minor sub-population of breast cancer patients with low grade tumors who are at higher risk.
Návaznosti
GA14-19250S, projekt VaVNázev: Nový panel proteinů korelujících se stavem lymfatických uzlin u low-grade nádorů prsu: Klinická verifikace a úloha v invazivitě nádorových buněk
Investor: Grantová agentura ČR, Nový panel proteinů korelujících se stavem lymfatických uzlin u low-grade nádorů prsu: Klinická verifikace a úloha v invazivitě nádorových buněk
VytisknoutZobrazeno: 26. 7. 2024 03:16